Compare ALLO & NVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ALLO | NVX |
|---|---|---|
| Founded | 2017 | 2012 |
| Country | United States | Australia |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Industrial Machinery/Components |
| Sector | Health Care | Miscellaneous |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 252.9M | 235.2M |
| IPO Year | 2018 | N/A |
| Metric | ALLO | NVX |
|---|---|---|
| Price | $1.80 | $0.90 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 12 | 0 |
| Target Price | ★ $8.27 | N/A |
| AVG Volume (30 Days) | ★ 6.3M | 1.2M |
| Earning Date | 03-12-2026 | 01-28-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $5,931,433.00 |
| Revenue This Year | N/A | $165.90 |
| Revenue Next Year | N/A | $1,344.85 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.86 | $0.81 |
| 52 Week High | $3.78 | $3.86 |
| Indicator | ALLO | NVX |
|---|---|---|
| Relative Strength Index (RSI) | 58.49 | 38.18 |
| Support Level | $1.56 | $0.83 |
| Resistance Level | $1.84 | $0.97 |
| Average True Range (ATR) | 0.16 | 0.06 |
| MACD | -0.01 | -0.01 |
| Stochastic Oscillator | 67.96 | 19.81 |
Allogene Therapeutics Inc is a clinical-stage biotech firm specializing in immuno-oncology, focusing on the development of genetically engineered allogeneic T-cell products for cancer and autoimmune diseases. Their pipeline includes off-the-shelf T-cell candidates designed to target cancer cells or autoreactive cells in autoimmune disorders. Notably, their allogeneic approach, derived from healthy donors, allows for broader patient eligibility and scalability. With a vision to redefine CAR T therapy, the company concentrates on core programs targeting lymphoma, leukemia, autoimmune diseases, and solid tumors. Revenue, generated from collaborations and licensing agreements, supports their research and development efforts.
NOVONIX Ltd operates in the lithium-ion battery industry. The company has three operating segments namely Graphite Exploration, Battery Technology, and Battery Materials. Graphite Exploration segment is engaged in the exploration and development of high-grade flake graphite deposits. The Battery Technology segment develops battery cell testing equipment and carries out research and development in battery development. The Battery Materials segment develops and manufactures battery anode materials. The Battery Technology segment generates maximum revenue for the company.